Ironwood Phase III Data Emphasizes Likely Linzess Label Expansion

Ironwood presented Phase III data on Linzess (linaclotide) at Digestive Disease Week for the treatment of 6-17 year-olds with functional constipation; US FDA approval is expected in a month.